34294-79-6

Basic information

• Product Name: (S)-3-AMINOPIPERIDINE-2-ONE
• Synonyms: (S)-3-AMINOPIPERIDINE-2-ONE ;(S)-3-aminopiperidin-2-one;(3S)-3-aMinopiperidin-2-one;(3S)-3-aMinopiperidin-2-one hydrochloride;(S)-3-AMinopiperidine-2-one HCl;(S)-3-AMino-piperidine-2-one hydrochloride;(S)-3-AMinopiperidin-2-one HCl;(S)-3-AMino-2-piperidinone
• CAS NO: 34294-79-6
• Molecular Formula: C₅H₁₀N₂O
• Molecular Weight: 114.1457
• Product Categories: CHIRAL CHEMICALS;Chiral heterocyclic compounds
• Mol File: 34294-79-6.mol

Chemical Properties

• Melting Point: 87°C(lit.)
• Boiling Point: 307.5 °C at 760 mmHg
• Flash Point: 139.8 °C
• Appearance: /
• Density: 1.071g/cm³
• Vapor Pressure: 0.000723mmHg at 25°C
• Refractive Index: 1.476
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• Solubility: Chloroform (Slightly, Sonicated), DMSO (Slightly), Methanol (Slightly)
• PKA: 16.00±0.40(Predicted)
• CAS DataBase Reference: (S)-3-AMINOPIPERIDINE-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-AMINOPIPERIDINE-2-ONE(34294-79-6)
• EPA Substance Registry System: (S)-3-AMINOPIPERIDINE-2-ONE(34294-79-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 34294-79-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-Aminopiperidine-2-one is used as a synthetic intermediate for the development of novel antitumor agents, specifically Thiazoleurea derivatives. These derivatives have demonstrated potential in targeting and treating various types of cancer, making (S)-3-Aminopiperidine-2-one a valuable component in the fight against cancer.

InChI:InChI=1/C5H10N2O/c6-4-2-1-3-7-5(4)8/h4H,1-3,6H2,(H,7,8)/t4-/m0/s1

Upstream product

• 81084-75-5 ornithine methyl ester 
• 1892-22-4 3-aminopiperidin-2-one 
• 16682-12-5 D-ornithine hydrochloride 
• 138377-80-7 3-aminopiperidin-2-one hydrochloride 
• 261522-14-9 ornithine methyl ester hydrochloride 
• 1069-31-4 DL-ornithine hydrochloride 
• 3184-13-2 L-ornithine hydrochloride 
• 1069-31-4 L-ornithine hydochloride 

Downstream Products

• 84772-30-5 3-(2'-aminobenzoyl)aminopiperidin-2-one 
• 3328-28-7 N-(2'-oxopiperidin-3'-yl)benzamide 
• 88763-76-2 (R)-(+)-3-Amino-2-piperidinon 
• 1422128-64-0 3-{[(5Z)-5-({1-[2,4-bis(trifluoromethyl)benzyl]piperidin-4-yl}methylidene)-2-oxo-2,5-dihydro-1,3-thiazol-4-yl]amino}piperidin-2-one 
• 1892-22-4 3-aminopiperidin-2-one 
• 606943-66-2 (3S)-3-(N-furfurylbenzyloxycarbonylamino)-2-piperidone 
• 606943-56-0 (3S)-3-(N-n-propylbenzyloxycarbonylamino)-2-piperidone 
• 606943-61-7 (3S)-3-(N-n-butylbenzyloxycarbonylamino)-2-piperidone 
• 61071-65-6 (S)-3-phthalimidopiperidin-2-one 
• 299215-37-5 3S-Amino-1Benzyl-piperidin-2-one 

Relevant articles and documents

PROTAC-mediated crosstalk between E3 ligases

Small-molecule heterobifunctional degraders can effectively control protein levels and are useful research tools. We assembled proteolysis targeting chimeras (PROTACs) from a cereblon (CRBN) and a von-Hippel-Lindau (VHL) ligase ligand and demonstrated a PROTAC-induced heterodimerization of the two E3 ligases leading to unidirectional and efficient degradation of CRBN.

Domino Reactions of Bis-Diazo Compounds: Rhodium(II) Acetate Catalyzed Diastereoselective Synthesis of Epoxy- and Epithio-Bridged Heterocycle-Fused Quinolizinone Analogues

Rhodium(II) acetate catalyzed domino reactions of bis-diazo compounds afford epoxy- and epithio-bridged heterocycle-fused quinolizinone systems in a stereoselective manner. The presence of an acceptor diazo functionality leads to a selective intermolecular X-H insertion reaction in a chemoselective manner, and the acceptor/acceptor diazo functionality subsequently participates in the formation of isomünchnone/thioisomünchnone 1,3-dipoles followed by intramolecular cycloaddition in a diastereoselective manner. This domino reaction is capable of constructing epoxy- and epithio-bridged heterocycle-fused quinolizinone ring systems with four stereogenic centers. The Bronsted acid induced reactions of oxa-bridged tricyclic compounds furnish ring-opened alcohol products in a regioselective manner.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The present invention provides a novel compound having a superior activity as an ERR-alpha modulator and useful as an agent for the prophylaxis or treatment of ERR-alpha associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof

Resolution of α-aminolactams by inclusion complexation with chiral host compounds

3-Aminopiperidin-2-one and α-amino-ε-caprolactam were efficiently resolved by inclusion complexation with a chiral host compound, (R,R)-(-)-trans-4,5-bis(hydroxydiphenylmethyl)-1,4-dioxaspiro[4.5]decane . The amino substituent on the lactam ring was found to play an important role in efficient chiral recognition in the inclusion crystals.

UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE

Urea derivatives represented by the following general formula (I) : which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the form

QUINAZOLINE DERIVATIVES

A quinazoline derivative of the formula (I) wherein: R1, R2, R3, R3a, R4, R5, R5a R6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula (I), are useful in the treatment of hyperproliferative disorders such as a cancer.

4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

The synthesis and chemistry of 3-diazo-piperidin-2-one

The efficient synthesis of 3-diazo-piperidin-2-one, from L-ornithine, in two steps is reported. The chemistry of this new cyclic α-diazoamide was explored and allows the rapid access to a wide range of 3-substituted piperidin-2-one derivatives.

Competitive intramolecular aminolysis: Relative rates of 5-and 6-membered lactam ring closure

Methyl 4,5-diaminopentanoate (4,5-Dape Me) undergoes competitive intramolecular aminolysis to 5-aminomethyl-2-pyrrolidinone (L5) and 5-amino-2-piperidinone (L6) in dilute alkaline aqueous solution at 25°C. Use of this single compound provides an ideal case for assessing the relative rates of 5- and 6-membered lactam ring closure. Assessments are also made using the intramolecular aminolysis of pairs of compounds: methyl 2,4-diaminobutanoate (2,4-Dab Me) and methyl 2,5-diaminopentanoate (2,5-Dape Me); methyl 4-aminobutanoate (4-Ab Me) and methyl 5-aminopentanoate (5-Ape Me).

Novel quinolonecarboxylic acid derivatives

Novel compounds of the present invention are represented by the general formula (1) STR1 wherein R1 is hydrogen atom or amino, R2 is fluorine atom or methoxy, R3 is hydrogen atom or a lower alkyl having 1 to 3 carbon atoms, and n is 0 or 1. The compounds of the general formula (1) exhibit higher antibacterial activity with fewer side-effects than known quinolone antibiotics such as ofloxacin and norfloxacin. Further, the compounds having the general formula (1) have reduced phototoxicity which normally accompanies 6,8-defluoroquinoline antibiotics.